title: Cyclin B1 expression is an independent prognostic marker for poor outcome in diffuse large B-cell lymphoma.
abstract: Diffuse large B-cell lymphoma (DLBCL) is the most frequent non-Hodgkin's lymphoma in the Western world; it is characterized by marked genetic, morphological and clinical heterogeneity. The identification of prognostic markers could help to develop risk-adapted treatment strategies. As proliferation of cells is essential for tumour growth, analysis of the cell cycle and its individual phases might give additional information on tumour progression and clinical behaviour. To investigate the prognostic value of proteins specifically related to the cell cycle phases S, G2 and M in DLBCL, the expression of cyclin A as a marker of S phase and cyclin B1 as a G2/M phase marker were analysed in combination with other clinicopathological parameters in a large cohort of patients. Expression of cyclin B1 and cyclin A were determined by immunohistochemistry using tissue microarray methodology. Immunoreactivity for cyclin B1 and cyclin A was correlated with clinical data using a two-sided Fisher's exact test. Impact on overall survival was analysed by the Kaplan-Meier method. A negative prognostic impact was found for expression of cyclin B1. Nuclear and/or cytoplasmic staining in > or = 1% of tumour cells was significantly associated with shorter overall survival in the multivariate analysis (p=0.008). Furthermore, the prognostic impact of cyclin B1 expression was independent of the tumour stage. No prognostic significance was found for expression of cyclin A. In conclusion, this study demonstrates the independent prognostic value of an expression of cyclin B1 in DLBCL and proposes its evaluation as a prognostic marker in the assessment of this entity which is easily applicable in daily routine practice.
authors.affiliation: Institute of Pathology, University of Regensburg, Franz-Josef-Strauss-Allee 11, 93053 Regensburg, Germany. ellen.obermann@klinik.uni-regensburg.de
authors.forename: Ellen C
authors.initials: EC
authors.lastname: Obermann
authors.forename: Philip
authors.initials: P
authors.lastname: Went
authors.forename: Ann-Christine
authors.initials: AC
authors.lastname: Pehrs
authors.forename: Alexandar
authors.initials: A
authors.lastname: Tzankov
authors.forename: Peter J
authors.initials: PJ
authors.lastname: Wild
authors.forename: Stefano
authors.initials: S
authors.lastname: Pileri
authors.forename: Ferdinand
authors.initials: F
authors.lastname: Hofstaedter
authors.forename: Stephan
authors.initials: S
authors.lastname: Dirnhofer
mesh_terms: D000368:Aged; D014408:Biomarkers, Tumor / Q000096:biosynthesis*; D019926:Cyclin B / Q000096:biosynthesis*; D056744:Cyclin B1; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D016393:Lymphoma, B-Cell / Q000378:metabolism / Q000473:pathology*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000378:metabolism / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D011379:Prognosis; D016019:Survival Analysis
chemical_list: D014408:Biomarkers, Tumor; C534699:CCNB1 protein, human; D019926:Cyclin B; D056744:Cyclin B1